Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Working reference

Storage and stability reference

What is known about how these molecules degrade, how long a lyophilised vial and a reconstituted solution actually last, what an excursion does, and which of the numbers circulating in this trade have a published basis.

Almost every storage figure in circulation in this trade has one of three origins: a manufacturer’s in-use statement for an approved product, a supplier’s assertion with no stated basis, or somebody’s recollection of a conversation. Only the first is a datum. This page separates them.

The organising distinction is between a lyophilised powder and a solution. A dry peptide with low residual moisture is a remarkably stable object: the reactions that degrade peptides mostly require water, and removing it removes most of the chemistry. A reconstituted solution is an entirely different proposition, and the difference is measured in orders of magnitude rather than percentages.

How peptides degrade

Four pathways account for most of what happens to a peptide in storage, and each has a characteristic signature on a chromatogram.

  • Deamidation. Asparagine and, more slowly, glutamine residues convert to aspartate or isoaspartate, adding 0.98 Da and usually producing an earlier-eluting peak. Strongly pH-dependent, accelerating above about pH 7.
  • Oxidation. Methionine, cysteine, tryptophan and histidine are susceptible; methionine oxidation adds 16 Da. Driven by dissolved oxygen, trace metals and light.
  • Hydrolysis. Backbone cleavage, favoured at extremes of pH and accelerated by temperature, producing truncated fragments that elute early.
  • Aggregation. Self-association into dimers, oligomers and eventually visible particulate. Often the first thing a user notices, and the one least visible on a reversed-phase chromatogram because aggregates may not elute at all.

All four are accelerated by temperature, and all four except aggregation are substantially slowed by removing water. That is the whole argument for lyophilisation, and it is why residual moisture content is the most important number on a lyophilised product’s specification — and one almost never reported on a research-grade certificate.1

Degradation pathways and their analytical signatures
PathwayMass changeTypical chromatographic behaviourPrincipal accelerant
Deamidation (Asn→Asp/isoAsp)+0.98 DaEarlier-eluting shoulder or resolved peakpH above neutral; temperature
Methionine oxidation+16 DaEarlier-eluting peak, more polarDissolved oxygen; light; trace metals
Tryptophan oxidation+16 / +32 DaMultiple minor earlier peaksLight; peroxides
Backbone hydrolysisvariable, largeMultiple early fragmentsExtremes of pH; temperature
Aggregationnone (non-covalent)Often not detected by RP-HPLC at allConcentration; agitation; freeze–thaw
Disulfide scrambling0 DaIsobaric; requires orthogonal methodpH above 7; reducing conditions
Mass changes are for the intact molecule. A 0 Da change is undetectable by mass alone and requires a separate method — which is the reason identity confirmation by mass is a weaker claim than it appears.

What the published shelf lives actually are

The table below distinguishes three tiers of evidence, and readers should treat them as three different kinds of statement. Manufacturer in-use data for an approved product is the strongest: it comes from a stability programme run to ICH conditions and reviewed by a regulator. Peer-reviewed compounding stability studies are next. Supplier assertions are not evidence and are marked as such.2

Storage guidance by evidence tier
ConditionGuidance in circulationEvidence tierWhat the Journal reports
Lyophilised, 2–8 °C, dark24–36 monthsManufacturer stability data for approved productsWell supported for approved presentations
Lyophilised, room temperature, darkweeks to monthsLimited; extrapolated from Arrhenius modellingPlausible; not established for research-grade material
Lyophilised, −20 °C"indefinite"Supplier assertionNo published basis; freeze–thaw is itself a stress
Reconstituted, 2–8 °C28–56 daysManufacturer in-use statements; some compounding studiesSupported for the products studied; not transferable
Reconstituted, room temperaturedaysManufacturer in-use limits for approved pensSupported only for the specific formulation
Reconstituted, frozencommonly assertedSupplier assertionFreezing a peptide solution risks aggregation; no basis
Excursion, single spike"probably fine"None specificMean kinetic temperature is the relevant measure, not the peak
In-use periods for approved products are properties of a specific formulation, including its buffer, preservative and container, and do not transfer to a differently formulated preparation. A compounded or research-grade preparation has no established in-use period unless somebody has run the study on that preparation.

An in-use shelf life is a property of a formulation, not of a molecule. Borrowing one product’s number for another product’s vial is not conservatism; it is guessing with a citation attached.

Lucía Berenguer

Mean kinetic temperature, and why the spike is the wrong number

Degradation integrates exposure over time. A shipment that spent four hours at 30 °C and eleven days at 6 °C has experienced less cumulative stress than one that sat at 22 °C for a fortnight, even though the first has the alarming peak reading. The quantity that captures this is mean kinetic temperature: a weighted average that gives disproportionate weight to higher temperatures, reflecting the exponential temperature dependence of reaction rates.

A data logger reporting only a maximum is therefore answering the wrong question, and so is a temperature indicator, which records only whether a threshold was crossed. Neither is useless — an indicator that has been breached tells you something real — but a breached indicator on a lyophilised powder and a breached indicator on a solution are findings of very different weight.

Reconstitution diluents

Bacteriostatic water — water containing roughly 0.9% benzyl alcohol — is widely used because the preservative suppresses microbial growth in a multi-dose vial. Sterile water without preservative does not, which is why unpreserved preparations are conventionally treated as single-use. Neither addresses chemical degradation: a preservative inhibits organisms, not deamidation.

Benzyl alcohol is not inert with respect to every peptide, and some formulations of approved products specifically avoid it. A reader should understand that the choice of diluent is a formulation decision being made by whoever reconstitutes the vial, without any of the stability data that would ordinarily support such a decision.

58422611-5.1relative rate510152025303540temperature (°C)relative rate (5 °C = 1)
Figure. Illustrative relative degradation rate against temperature for a first-order process with a typical activation energy, normalised to 1 at 5 °C. Model output, not measured data: it shows why a few degrees matters more than intuition suggests.

What we would need to know and do not

  • Residual moisture content of research-grade lyophilised material. Not reported by any of the twenty suppliers the Journal tracks as a standard release test.
  • Container closure integrity. Not tested, not claimed.
  • Real stability data on the specific preparations in circulation. There is essentially none: the published studies are on approved formulations or on compounded preparations made to a documented recipe.
  • What actually happened in transit. Three of twenty suppliers ship without any temperature indicator, which means the excursion is undocumented rather than absent.

The honest summary is that the storage advice circulating in this trade is a mixture of well-founded manufacturer data borrowed from a different product, sensible extrapolation, and confident invention — and that almost nobody distinguishes the three. This page exists to make the distinction available.

Not medical advice

This is a reference page published as journalism. It is not guidance on preparing, storing or administering anything. Compounds sold for research use only are not approved for human use in any jurisdiction.

References

  1. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. “Stability of Protein Pharmaceuticals: An Update.” Pharmaceutical Research. 2010;27(4):544–575.
  2. International Council for Harmonisation. Q1A(R2): Stability Testing of New Drug Substances and Products. 2003.